Phase III Study Comparing the Efficacy of Paclitaxel-bevacizumab With Docetaxel in 2nd or 3rd Line of Treatment of Non Squamous Non Small Cells Lung Cancer
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
Progression free survival
Time between inclusion and progression
about 4 months
No
Alexis CORTOT, MD
Principal Investigator
CHRU Lille
France: Agence Nationale de Sécurité du Médicament et des produits de santé
IFCT-1103
NCT01763671
March 2013
June 2015
Name | Location |
---|